BioPharma Resources

Drugs by condition

Drugs approved for overactive bladder

Brand-name prescription drugs and biologics whose FDA label lists overactive bladder as an approved use. Matched on the label phrases: "overactive bladder".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

7

Still marketed, NDA or BLA

Drug classes

4

Novel drugs

5

New molecular entities and new biologics

In development

1

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for overactive bladder.

  • Myrbetriq Granules (Mirabegron) · Apgdi Priority reviewMar 25, 2021
  • Gemtesa (Vibegron) · Sumitomo Pharma Am NovelDec 23, 2020
  • Myrbetriq (Mirabegron) · Apgdi NovelJun 28, 2012
  • Toviaz (Fesoterodine Fumarate) · Pfizer NovelOct 31, 2008
  • Oxytrol (Oxybutynin) · Allergan Feb 26, 2003

All approved drugs for overactive bladder, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 60 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

beta3-Adrenergic Agonist (3)

Acetylcholine Release Inhibitor (1)

Cholinergic Muscarinic Antagonist (1)

  • Oxytrol Oxybutynin · Allergan · 2003

Class not listed in FDA's data (2)

  • Toviaz Fesoterodine Fumarate · Pfizer · 2008
  • Detrol Tolterodine Tartrate · Upjohn · 1998

Drugs in development for overactive bladder

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • TRG-200Phase 21 trial

    Trigone Pharma Ltd. · Overactive Bladder (OAB)

More on overactive bladder: recruiting trials · published research

Related in kidney and urology: Chronic kidney disease · IgA nephropathy · Enlarged prostate (BPH) · Erectile dysfunction

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.